Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

322 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A, Fumarola C, Bonelli M, Generali D, Petronini PG. La Monica S, et al. Among authors: generali d. Biochem Pharmacol. 2009 Sep 1;78(5):460-8. doi: 10.1016/j.bcp.2009.04.033. Epub 2009 May 7. Biochem Pharmacol. 2009. PMID: 19427302
Synergistic activity of letrozole and sorafenib on breast cancer cells.
Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, Gatti R, Belletti S, Harris AL, Fox SB, Evans DB, Dowsett M, Martin LA, Bottini A, Generali D, Petronini PG. Bonelli MA, et al. Among authors: generali d. Breast Cancer Res Treat. 2010 Nov;124(1):79-88. doi: 10.1007/s10549-009-0714-5. Epub 2010 Jan 7. Breast Cancer Res Treat. 2010. PMID: 20054642
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
Cavazzoni A, Bonelli MA, Fumarola C, La Monica S, Airoud K, Bertoni R, Alfieri RR, Galetti M, Tramonti S, Galvani E, Harris AL, Martin LA, Andreis D, Bottini A, Generali D, Petronini PG. Cavazzoni A, et al. Among authors: generali d. Cancer Lett. 2012 Oct 1;323(1):77-87. doi: 10.1016/j.canlet.2012.03.034. Epub 2012 Apr 3. Cancer Lett. 2012. PMID: 22484466
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".
Foroni C, Milan M, Strina C, Cappelletti M, Fumarola C, Bonelli M, Bertoni R, Ferrero G, Maldotti M, Takano E, Andreis D, Venturini S, Brugnoli G, Petronini PG, Zanoni V, Pritzker L, Pritzker K, Parissenti A, Santini D, Fox SB, Bottini A, Generali D. Foroni C, et al. Among authors: generali d. Breast Cancer Res Treat. 2014 Feb;144(1):113-21. doi: 10.1007/s10549-014-2840-y. Epub 2014 Jan 28. Breast Cancer Res Treat. 2014. PMID: 24469643 Clinical Trial.
CDK4/6 inhibitors in HER2-positive breast cancer.
Corona SP, Ravelli A, Cretella D, Cappelletti MR, Zanotti L, Dester M, Gobbi A, Petronini PG, Generali D. Corona SP, et al. Among authors: generali d. Crit Rev Oncol Hematol. 2017 Apr;112:208-214. doi: 10.1016/j.critrevonc.2017.02.022. Epub 2017 Feb 24. Crit Rev Oncol Hematol. 2017. PMID: 28325261 Review.
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
Cretella D, Ravelli A, Fumarola C, La Monica S, Digiacomo G, Cavazzoni A, Alfieri R, Biondi A, Generali D, Bonelli M, Petronini PG. Cretella D, et al. Among authors: generali d. J Exp Clin Cancer Res. 2018 Mar 27;37(1):72. doi: 10.1186/s13046-018-0741-3. J Exp Clin Cancer Res. 2018. PMID: 29587820 Free PMC article.
322 results